Analyst consensus rating
Immix Biopharma Analyst Rating: Strong Buy
IMMX is rated Strong Buy by 8 analysts with a $20.28 target. As of 2026-08-27.
Direct answer
Immix Biopharma's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.28.
Forecast evidence checked August 27, 2026.
Get free Immix Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $14.07
- Average price target
- $20.28
- High price target
- $27.00
- Low price target
- $13.20
- Low target gap
- -6.2%
- Target upside
- +44.1%
- High target gap
- +91.9%
- Target range width
- 98.1%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Immix Biopharma?
Immix Biopharma has a verified Strong Buy consensus. The same dataset has an average price target of $20.28.
How far are Immix Biopharma's low and high targets from the recorded price?
The low target implies -6.2%, while the high target implies +91.9%.
How many analysts are included in Immix Biopharma's consensus?
The verified consensus includes 8 analysts.
How is Immix Biopharma's target upside or downside calculated?
The average target of $20.28 is divided by the recorded price of $14.07, then one is subtracted to produce +44.1%. This does not guarantee a future return.
When was Immix Biopharma's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.